Business
SK bioscience, IDT Biologika and Vaxxas Selected for Next-Generation Influenza Vaccine development Financed by the European Union
SK bioscience announced that, together with IDT Biologika (IDT) and Australian biotechnology company Vaxxas, it has been selected for Phase 1 of a next-generation vaccine development initiative managed by the European Health and Digital Executive Agency (HaDEA) on behalf of the European Commission's Health Preparedness and Response Authority (HERA). Using Vaxxas' needle-free delivery technology, the three-party consortium will develop a seasonal influenza vaccine for older adults and pandemic in
About this update from Sk Bioscience Co.,ltd.
[{"type":"list","items":[{"val":[{"type":"text","content":"SK–IDT–Vaxxas consortium establishes strategic entry point for high-density microarray patch (HD-MAP) vaccines in Europe to improve vaccine performance and access.","length":163,"tagName":"p"}]},{"val":[{"type":"text","content":"Parallel development of high-immunogenicity HD-MAP vaccines for seasonal and pandemic influenza threats.","length":104,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":267,"olType":false},{"type":"text","content":"INCHEON, South Korea, Feb. 26, 2026 /PRNewswire/ -- SK bioscience announced that, together with IDT Biologika (IDT) and Australian biotechnology company Vaxxas, it has been selected for Phase 1 of a next-generation vaccine development initiative managed by the European Health and Digital Executive Agency (HaDEA) on behalf of the European Commission's Health Preparedness and Response Authority (HERA). Using Vaxxas' needle-free delivery technology, the three-party consortium will develop a seasonal influenza vaccine for older adults and pandemic influenza vaccine for broader populations.","length":600,"tagName":"p"},{"type":"image","alt":"SK bioscience (PRNewsfoto/SK bioscience)","displaySize":"","headline":null,"caption":"SK bioscience (PRNewsfoto/SK bioscience)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":400,"url":"https://media.zenfs.com/en/prnewswire.com/c30fedfd557e5c0b54e71f73f7494452"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/1LrnM2rO37fBHeeyu9uvMw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTcwNTtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/c30fedfd557e5c0b54e71f73f7494452","width":400,"height":400}},"href":"https://mma.prnewswire.com/media/1979527/SK_bioscience_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"This contract is one of three EU-funded framework contracts, valued at up to a total of €225M and aimed at strengthening next-generation vaccine commercialization and supply capabilities within Europe. HaDEA will provide up to €12.9 million to support Phase 1 research, including a Phase 1 clinical trial. Subject to successful technical validation and clinical outcomes, the Consortium could tender to progress through subsequent phases of the program to support Phase 3 and final-stage development.","length":500,"tagName":"p"},{"type":"text","content":"The co...